<DOC>
	<DOCNO>NCT00422318</DOCNO>
	<brief_summary>The study aim ass ( I ) contribution UA CHF pathophysiology ( II ) test effect lower UA uricosuric treatment CHF .</brief_summary>
	<brief_title>Treatment Hyperuricemia Patients With Heart Failure</brief_title>
	<detailed_description>Hyperuricemia often observe patient congestive heart failure ( CHF ) . It report hyperuricemia relate exercise capacity , inflammation marker diastolic dysfunction patient . In addition , hyperuricemia CHF relate symptomatic status ( i.e . morbidity ) well impaired prognosis ( i.e . mortality ) . Hyperuricemia likely play important role pathophysiology CHF . Up-regulation xanthine oxidase ( XO ) activity CHF show contribute high uric acid ( UA ) CHF therapeutic concept XO inhibition show beneficial effect number surrogate marker patient . The XO inhibition account substantial decrease oxygen radical load , latter discuss main benefit XO inhibition treatment hyperuricemic patient . However , whether high uric acid important merely marker XO activity ( hence increase radical accumulation ) currently discussion . Therefore , study aim ass ( I ) contribution UA CHF pathophysiology ( II ) test effect lower UA uricosuric treatment CHF .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Hyperuricemia</mesh_term>
	<mesh_term>Benzbromarone</mesh_term>
	<criteria>chronic heart failure hyperuricemia renal dysfunction ( Cr &gt; 2.0 mg/dl ) treatment antidiabetic agent</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2007</verification_date>
	<keyword>Heart Failure</keyword>
	<keyword>Insulin</keyword>
	<keyword>Metabolism</keyword>
	<keyword>Pharmacology</keyword>
	<keyword>Uric Acid</keyword>
</DOC>